| Cancer hallmarks | Therapeutic targeting |
| Evading growth suppressors | Cyclin-dependant kinase inhibitors |
| Sustaining proliferative signalling | EGFR inhibitors |
| Resisting cell death | Pro-apoptotic BH3 mimetics |
| Enabling replicative immortality | Telomerase inhibitors |
| Inducing angiogenesis | Inhibitors of VEGF signalling |
| Avoiding immune destruction | Immune activating anti-CTLA4 monoclonal antibody |
| Tumour promoting inflammation | Selective anti-inflammatory drugs |
| Genome instability and mutation | PARP inhibitors |
| Deregulating cellular energetics | Aerobic glycolysis inhibitors |
| Activating invasion and metastasis | Inhibitors of HGF/c-Met |
EGFR: epithelial growth factor receptor; VEGF: vascular endothelial growth factor; CTLA4: cytotoxic T lymphocyte-associated antigen 4; PARP: poly ADP-ribose polymerase; HGF: hepatocyte growth factor.